

INDEX

A

N-Acetyl-galactosamine, 134, 135
 Acidic ginsenosides in roots, UV detection, 50–54
 Acrylonitrile–psyllium grafted copolymer, 214
 Adherence (pathogenic bacteria), 101–161
 common mechanisms of, 117–128
 inhibitors, 103, 128–139
 kinetics, 105–106
 specificity, 107
 Adhesins, 114–117
 adhesion mechanisms, 117–128
 analogs as anti-adhesins, 129, 132–133
 Adipocytes and ginsenosides, 78
 Afa adhesins, 128
 Afimbrial adhesins, 116–117
 Airway *see* Respiratory system
 Alkaline treatment of psyllium, 214
 Allergy
 ginsenoside effects, 71–72
 occupational causes, 169–176
 psyllium-induced, 204
 reducing, 206, 215
 AlpA and Alp B, 121
 Alveolitis, extrinsic allergic *see*
 Hypersensitivity pneumonitis
 α -Amylase
 glucoamylase preparations contaminated
 with, 236
 respiratory allergy, 175–176
 Amylopectin polymers in starch, 224
 high-amylopectin starches, 224
 structure, 226–228
 Amylose polymers in starch, 224
 high-amylose starches, 224
 structure, 226–227
 Anaphylaxis
 occupational causes, 170
 passive cutaneous, ginsenosides
 and, 72
 Angiogenesis, tumor, ginsenoside
 effects, 68

Anisotropy, starch granules, 226–227
 Anti-adhesive agents, 103, 128–139
 Antibodies (use)
 allergen sensitization tests, 167, 168
 anti-adhesin, 130
 anti-ginsenoside, 62–63 *see also* Vaccines
 Anticancer effects *see* Cancer
 Antihypertensive effects, ginsenosides, 72–73
 Anti-inflammatory effects of ginsenosides, 71–72
 Apoptosis and ginsenosides, 66
 Asthma (occupation-related), 169–177
 allergic, 169–176
 irritant-induced, 172, 176–177
 work-aggravated, 176–177
 Atherosclerosis and ginsenosides, 72–73
 Atmospheric pressure chemical ionization (APCI), ginsenosides, 57
 Auf fimbriae, 128

B

BabA, 120, 120–121
 Bacteria
 intestinal (commensal) *see* Microflora
 pathogenic, adherence *see* Adherence
 Baking industry, respiratory allergy, 175–176
 BFP (bundle-forming pili)
 enterohemorrhagic *E. coli*, 126
 enteropathogenic *E. coli*, 122–123
 Bifidobacteria, anti-adhesin activity, 131, 136, 138
 Bile acids and psyllium, 201
 Birefringence of starch granules, 225–228
 loss in gelatinization, 233–235
 Bowel *see* Intestine
 Breast cancer
 ginsenoside effects, 65, 66
 psyllium effects, 202–203
 Bronchiolitis obliterans/BO (occupation-related), 178–186

Bronchiolitis obliterans/BO (occupation-related) (*cont.*)
 flavoring-related, 164, 179–186
 medical test results, 171
 site/description/causes, 173
 Bronchitis (occupation-related chronic), 170, 177
 medical test results, 173
 site/description/causes, 173
 Bronchodilator trial, 166, 168
 in occupational lung disease, 171
 Bronchoprovocation test, 166, 168
 Bundle-forming pili *see* BFP
 Butter flavorings (in microwave popcorn), 164, 179, 181, 182, 184, 185, 187
 2-*tert*-Butylanthraquinone, 57

C

Cadherins and pathogen adherence, 113, 114
 Calcium and psyllium, 204
 Calorimetry, differential scanning (DSC), starch gelatinization studies, 238–247, 249, 250, 253, 254, 256, 258–260
 Cancer (prevention and management)
 ginsenoside effects, 35, 64–68, 70
 psyllium effects, 202–203
 Capillary electrophoresis, ginsenosides, 61
 Carbohydrase treatment of psyllium, 207
 Carbohydrates (incl. oligosaccharides), bacterial receptor, 103, 106–108
 analogs, anti-adhesive activity, 133–139
 in specific pathogen–host interactions, 108–117
 Carbon monoxide diffusing capacity (DL_{CO}), 167, 168–169
 in occupational lung disease, 171
 Carcinogenesis *see* Cancer
 Cardiovascular effects, ginsenosides, 72–73
see also Coronary heart disease
 Carrot extracts, 134, 138
 Central nervous system and ginsenosides, 74–76
 Chemical modification of psyllium, 214–215
 Chest, high-resolution CT *see* High-resolution CT
 Chikusetsusaponin, 4, 11, 12, 14, 16, 20
 Cholesterol-lowering activity of psyllium, 195–201, 213
 Cholinergic system and ginsenosides, 74–75
 Chromatography (of ginsenosides)
 gas, 48–49

immunostaining after
 (immunochromatography), 63
 liquid *see* Liquid chromatography
 thin-layer, 46–48
 Coating of psyllium granules, 205
 Collagen-binding adhesins, 113, 115, 117
 Collision-induced dissociation (CID)
 methodology, ginsenosides, 58
 Colon/colorectal cancer
 ginsenoside effects, 66, 67
 psyllium effects, 202
 Compensation, flavoring-related
 bronchiolitis obliterans, 185–186
 Compound K (M1; IH-901), 37
 anticancer activity, 66
 intestinal synthesis, 33–35
 Computed tomography, high-resolution *see* High-resolution CT
 Conjunctivitis, occupational allergic, 169–170
 Constipation, psyllium in, 203
 Corn starch gelatinization, birefringence loss, 235
 Coronary heart disease, hypolipidemic effects of psyllium in prevention of, 195–201, 213
 Coulombic forces and pathogen adherence, 105
 Cranberry extracts, 134, 137–138
 Crystalline structure/crystallites of starch, 225–228
 crystallite melting theory (of Flory), 240, 242–243, 250–253
 crystallite stability theory, 241–244
 polymorphic groups, 228–230
 water availability theory and, 238–241
 Csg operon, 119
 Cycloartenol, biosynthesis, 45
 Cytokines and ginsenosides, 69, 71, 73
 Cytotoxicity, ginsenosides, 65–67

D

Dammarane-type triterpene saponins, 3, 23, 40
 biosynthesis, 38, 40, 41, 45
P. notoginseng, 30
 20(R)-Dammarane-3 β , 6 α , 20, 25-pentol, 44
 20(R)-Dammarane-3 β , 12 β , 20, 25-tetrol, 7
 Dammaranediol-type ginsenosides, 41
 20(S)-dammaranediol, 22
 Dammarenyl cation, 38–41, 41

Defences

- immune, ginsenoside effects, 69–70
- respiratory tract, 165

Dendritic cells, ginsenoside effects, 69, 70

Diabetes

- ginsenosides and, 77–79
- psyllium and, 201–202

Diacetyl (in microwave popcorn), 179

Differential scanning calorimetry (DSC),
starch gelatinization studies, 238–247,
249, 250, 253, 254, 256, 258–260Differential thermal analysis (DTA), starch
gelatinization studies, 238, 239–240Dimethylallyl diphosphate (DMAPP), 37,
38, 39Donovan's water availability theory (for
starch gelatinization), 238–241, 243

Dr adhesins, 128

E

Eastern blots, ginsenosides, 63

ECP, 126

Efa-1 adhesin, 122, 124, 125

Egg yolk-derived sialyloligosaccharides,
134, 136–137

Electrophoresis, capillary, ginsenosides, 61

Electrospray ionization (ESI), ginsenosides,
57–60ELISA (enzyme-linked immunosorbant
assay), ginsenosides, 62Emphysema, occupation-related, 178
medical tests results, 171
site/description/causes, 173Emulsifier-coated psyllium granules, 205
Enterohemorrhagic *E. coli* adhesion,
125–126Enteropathogenic *E. coli* adhesion, 122–124

Enzymatic methods

- of psyllium treatment, 206–214
conventional, 206–207
solid-state, 207–214
- of starch gelatinization measurement,
234, 236

Enzyme immunoassays, ginsenosides,
61–62Epithelial cells, intestinal, as pathogen
target, 111*Escherichia coli* adhesion, 107, 122–128
enterohemorrhagic, 125–126
enteropathogenic, 122–124
target molecules, 110
uropathogenic (UPEC), 102, 114, 126–128

EspA, 122, 123

Ethanol extraction of ginsenosides, 45

Evaporate light scattering detection of
ginsenosides, 55–56

Excitotoxicity and ginsenosides, 75–76

Extracellular matrix (ECM) and pathogen
adherence, 111, 113–114

F

F1C fimbriae, 127

F9 fimbriae, 125

Fecal bulk, psyllium effects, 203

Fibronectins, 115

- proteins (adhesins) binding to (FnBPs),
109, 113, 115, 116–117

Fimbrial (pillar) adhesins, 114–116

E. coli

enterohemorrhagic, 125–126

uropathogenic, 126–128

Salmonella, 117–118Flagella, enteropathogenic *E. coli*, 124

Flavoring-related bronchiolitis obliterans, 164

Floralginsenoside, 8, 9, 12, 13, 15, 16

Floralquinenoside, 9, 15, 16

Flory's theory (of starch gelatinization), 240,
242–243, 250–253

Flours, respiratory allergy, 175–176

Flower buds, ginsenosides, 24–29

Fluorescence detection of ginsenosides,
56–57

Fruits, ginsenosides, 24–29

G

GABA and ginsenosides, 76

Galacto-oligosaccharides, 134, 138–139

Gas chromatography, ginsenosides, 48–49

Gastric acids and ginsenosides, 33, 34, 35, 36

Gastrointestinal effects of psyllium, 203–204

Gelatinization of starch *see* StarchGinseng *see* *Panax*

Ginsenosides, 1–99

analysis, 45–64

biosynthesis, 37–45

chemistry, 23–45

classification, 2, 3, 23

health benefits, 64–79

metabolism, 33–37

pharmacokinetics, 33–37, 48, 55, 79

preparation from ginseng, 32–33

sample extraction, 45–46

Glass transition, starch, 255–258

Globotriose, 134, 135
 Glucoamylase, starch gelatinization estimation using, 234, 236
 Glucose
 blood
 ginsenoside effects, 77, 78–79
 psyllium effects, 201
 in starch, units of, 224
 Glucose transporter 4 (GLUT-4)
 ginsenosides and, 78
 psyllium and, 201
 Glutamate and ginsenosides, 75–76
 Glycocalyx and pathogen adherence, 111, 112–113
 Glycosidic bonds, starch, 224
 Goblet cells
 airway, 165
 intestinal, 104
 Granules, starch
 disruption *see* Starch, gelatinization
 structure, 224–229
 GRAS (“generally recognized as safe”)
 classification, 186
 Green tea extracts, 134, 138
Gynostemma pentaphyllum, distribution of
 ginsenosides, 29, 31
 Gypenoside, 5

H

HcpA, 126
 HDL-cholesterol, psyllium effects, 196, 199
 Heart disease, coronary, hypolipidemic effects of psyllium in prevention of, 195–201, 213
Helicobacter pylori adhesins, 119–120
 Hemsloside-Ma₃, 30
 Hepatic cancer cells, ginsenoside effects, 66, 67
 High-density lipoprotein (HDL)-cholesterol, psyllium effects, 196, 199
 High-performance liquid chromatography of ginsenosides, 49–61
 High-performance thin-layer chromatography of ginsenosides, 48
 High-resolution CT in lung disease, 167, 169
 occupational lung disease, 171
 High-resolution MS, ginsenosides, 60–61
 HopH, 121
 HopZ, 121
 HorB, 121–122
 Hot stage microscopy, starch gelatinization measurement, 234

Human milk oligosaccharides, 134, 136
 Hydrogen bonds and pathogen adherence, 105–106
 Hydrophobic interactions (and hydrophobins) and pathogen adherence, 105, 108, 110–111
 Hyperglycemia reduction *see* Hypoglycemic effects
 Hyperlipidemia, psyllium effects, 195–201, 213
 Hypersensitivity pneumonitis (extrinsic allergic alveolitis), occupation-related medical test results, 171, 177–178
 site/description/causes, 173
 symptoms, 170
 Hypertension and ginsenosides, 72–73
 Hypoglycemic effects
 ginsenosides, 77, 78–79
 psyllium, 201–202
 Hypolipidemic effects of psyllium, 195–201, 213

I

IH-901 *see* Compound K
 Immunization, adhesin
 active (=vaccination), 117, 130
 passive, 130
 Immunoassays, ginsenosides, 61–62
 Immunomodulatory effects of ginsenosides, 69–70
 Infection, bacterial
 adherence in *see* Adherence
 routes, 103–105
 Inflammation, ginsenoside effects, 71–72
 Insulin sensitivity
 ginsenoside effects, 78
 psyllium effects, 201–202
 Integrins and pathogen adherence, 113, 114
 Interleukin-6 and ginsenosides, 72–73
 Intestine (bowel)
 cancer, ginsenoside effects, 66
 microflora *see* Microflora
 pathogens in
 routes of infection, 103–105
 target tissues, 111–114
 pharmacokinetics and metabolism of
 ginsenosides, 33–35
 psyllium effects on movement, 203
 Intimin, 124
 Invasion, tumor, ginsenoside effects, 35, 67–68
 Irritable bowel syndrome, psyllium, 203

Irritant-induced asthma, 172, 176–177
 Isopentenyl diphosphate (IPP), 37, 38, 39

K

Kofler stage microscopy, starch
 gelatinization measurement, 234
 Koryoginsenoside, 11, 13

L

Lactobacillus, anti-adhesin activity, 131–132
 Lactosylceramide and pathogen adherence, 113
 Laxative effects of psyllium, 203
 LDL-cholesterol, psyllium effects, 197, 199, 213
 Learning and ginsenosides, 74–75
 Leaves, ginsenosides, 24–29
 Lectin–carbohydrate interactions in
 bacterial adhesion, 108, 108–109, 113
 Legal liability, flavoring-related
 bronchiolitis obliterans, 185–186
 Leukemia cells, ginsenoside effects, 65
 Liability, flavoring-related bronchiolitis
 obliterans, 185–186
 LfA, 124
 Lipid-lowering activity of psyllium,
 195–201, 213
 Lipoteichoic acid (LTA), 132–133
 Liquid chromatography of ginsenosides
 high-performance, 49–61
 and mass spectrometry (LC-MS), 57–60
 ultra-performance, 61
 Liver (hepatic) cancer cells, ginsenoside
 effects, 66, 67
 Long polar (LP) fimbriae, *Salmonella*, 117,
 118
 Low-density lipoprotein (LDL)-cholesterol,
 psyllium effects, 197, 199, 213
LpfABCC'DE fimbrial operon,
 enterohemorrhagic *E. coli*, 125
LpfABCDE fimbrial operon, *Salmonella*, 118
 Lung *see* Respiratory system
 Lymphocytes, ginsenoside effects, 69–70
 Lymphostatin, 124

M

M1 *see* Compound K
 Macrophages, ginsenoside effects, 70
 Majonoside, 19, 20
 Majoroside, 7, 8, 14

Malignancy *see* Cancer
 Malonyl-ginsenosides, 23–32
 HPLC-UV detection, 50–54
 mass spectroscopy, 59
 Manno-oligosaccharides, 134, 138
 Mass spectrometry (MS), ginsenosides,
 57–61
 Medical surveillance for food industry
 allergy, 176
 Melanoma cells, ginsenoside effects, 66, 67,
 68
 Melting of polymer in starch gelatinization
 Flory's theory, 240, 242–243, 250–253
 in three-stage phase transition theory, 250
 Memory and ginsenosides, 74–75
 Metabolism
 ginsenoside effects on, 76–77
 of ginsenosides, 33–37
 Metastasis, tumor, ginsenoside effects, 35,
 67–68, 68
 Methacholine provocation test, 166–167, 168
 in occupational lung disease, 171
 Methacrylic acid derivatives of psyllium,
 214
 Methanol extraction of ginsenosides, 45
 Methyl- α -mannoside, 134, 135
 Mevalonic acid, 37
 Microbial surface components recognizing
 adhesive matrix molecules
 (MSCRAMMs), 109, 116
 Microflora, intestinal, 105
 ginsenoside metabolism by, 33–35, 36
 Milk (human) oligosaccharides, 134, 136
 Monoclonal antibodies
 to ginsenosides, 62–63
 to *S. mutans*, 130
 MSCRAMMs (microbial surface
 components recognizing adhesive
 matrix molecules), 109, 116
 Mucus (and mucins)
 intestinal, and pathogen adherence,
 104–105, 112, 131
 respiratory tract, defence role, 165

N

National Institute for Occupational Safety
 and Health (NIOSH) and microwave
 popcorn flavoring, 164, 179–182
 Near infrared spectroscopy, ginsenosides,
 63–64
 Neovascularization, tumor, ginsenoside
 effects, 68

Neurological effects, ginsenosides, 74–76
 Neurotransmitters and ginsenosides, 76
 Neutrophil-activating protein, *H. pylori*, 120
 Nitric oxide and ginsenosides, 71–72
 Notoginsenoside, 5, 7, 8, 9, 13, 14, 16, 18, 22, 23
 Nuclear magnetic resonance spectroscopy, ginsenosides, 61

O

Obesity, orlistat, 204
 Occupational respiratory disease, 164, 169–176
 new/emerging, recognition, 186–187
 prevention, 187
 types, 169–179
 Occupational Safety and Health
 Administration (OSHA) and flavoring-related bronchiolitis obliterans, 179, 185
 Ocotillol (and ocotillol-type ginsenosides), 19, 23, 30, 31
 biosynthesis, 41, 43
 Oleanane-type triterpene saponins, 3, 23, 40
 biosynthesis, 41, 45
 Oleanolic acid-type ginsenosides, 20, 23, 30, 31
 biosynthesis, 44
 Oligosaccharides as bacterial receptors *see* Carbohydrates
 Orlistat, 204
 Outer membrane proteins (OMPs) as adhesins, 120–122
 Ovarian cancer cells, ginsenoside effects, 66

P

P-fimbriae/pili (pyelonephritis-associated pill), 114–115, 127
Panax (ginseng), 44–45
 bipinnatifidus (feather-leafed bamboo ginseng), 24
 distribution of ginsenosides in, 24–29
 ginseng (Korean/Asian/Chinese ginseng), 3, 24–25, 30
 japonicus (Japanese ginseng), 3, 25–26
 notoginseng (Sanchi ginseng), 3, 26, 30–31
 pseudoginseng, 26, 27
 quality markers, 30

quinquefolium (American ginseng), 3, 27–28, 30
 steaming and drying, 32–33
stipuleanatus (Pingpien ginseng), 28
trifolius (Dwarf Ginseng), 28
vietnamensis (Vietnamese ginseng), 3, 28–29
zingiberensis (Ginger ginseng), 29
 20(S)-Panaxatriol, 21
 Pancreatic cancer cells, ginsenoside effects, 67
Pap (pyelonephritis-associated pili), 114–115, 127
 Passive cutaneous anaphylaxis and ginsenosides, 72
 Pathogenic, bacteria, adherence *see* Adherence
 Peak expiratory flow (PEF), 166, 168
PefBACD fimbrial operon, *Salmonella*, 118–119
 Pentopan Mono BG treatment of psyllium, 208, 209, 210–211, 211
 Peroxide proliferator-activated receptors (PPARs) and ginsenosides, 76–77
 and diabetes, 78
 Pharmacokinetics, ginsenosides, 33–37, 48, 55, 79
 Phase transition theory (starch gelatinization), 244–250, 258–260
 sequential, 244–249
 three-stage, 250, 258
 Phosphate buffer, ginsenoside detection, 50–54
 Pili *see* Fimbrial adhesins
 Plant(s)
 ginsenosides in, 2–3
 distribution in, 23–32
 starches from, 222–223, 223
Plantago, 194
 Plasmid-encoded (PE) fimbriae, *Salmonella*, 117, 118–119
 Pneumonitis, hypersensitivity *see* Hypersensitivity pneumonitis
 Polarized light, starch gelatinization measurement, 234
 Polyacetyleneginsenoside Ro, 21, 45
 Polymers
 melting (in starch gelatinization) *see* Melting
 psyllium effects on functional properties, 214–215

- Polyvinylpyrrolidone-coated psyllium granules, 205
- Popcorn (microwave) flavoring, 164, 179–182, 183, 184, 185, 186
- Potato starch gelatinization, 241–242, 247 birefringence loss, 235
- Prebiotics as anti-adhesins, 103, 135–136, 138–139
- Probiotics as anti-adhesins, 129, 131–132
- Prodrug, ginsenoside Rb₁ as, 59
- Prostaglandins and ginsenosides, 71
- Prostate cancer cells, ginsenoside effects, 65, 66
- Protein(s), as adhesin analogs, 132–133
- Protein–protein interactions in bacterial adhesion, 108, 109
- Proteolysis, psyllium, 206
- Protopanaxadiol (PPD)-type ginsenosides, 4–23
 anticancer effects, 65, 66
 biosynthesis, 41, 42
 gas chromatography, 49
 pharmacokinetics and metabolism, 33–37
- Protopanaxatriol (PPT)-type ginsenosides, 12, 13, 19, 23
 anticancer effects, 65, 66–67
 biosynthesis, 42, 43
 ELISA, 63
 gas chromatography, 49
 metabolism, 36
- Pseudo-ginsenoside, 5, 13, 19, 20
- Psyllium, 193–219
 adverse effects, 204
 reducing, 204–214
 health benefits, 194, 195–204
 improving functionality and biological activity, 194–195, 204–214
- Pyelonephritis-associated pili (*pap*), 114–115, 127
- Q**
- Quadrupole-MS (LC-MS), ginsenosides, 57–60, 61
- Quinqueside, 5, 6, 7, 9, 18, 22
- R**
- Receptors for bacteria, 102–103, 106–107
 analogs as anti-adhesins, 129, 133–139
 carbohydrates as *see* Carbohydrates
- in specific pathogen–host interactions, 108–117
- Respiratory system (inc. lung), 163–198
 anatomy and defences, 165
 cancer cells, ginsenoside effects, 65, 67, 68
 disease, 163–192
 diagnosis, 165–167
 occupational *see* Occupational respiratory disease
- Rhinitis, occupational allergic, 169–170, 174, 175, 176, 187
- Rhizomes *see* Roots and rhizomes
- Rice starch gelatinization, birefringence loss, 235
- Roots and rhizomes containing ginsenosides, 24, 31
 preparation by steaming and drying, 32–33
 UV detection of ginsenosides, 50–54
- S**
- S-fimbriae, 127–128
- SabA, 121
- Salmonella* adherence, 117–118
- Saponins, triterpenoid *see* Triterpenoid saponins
- Selectins and pathogen adherence, 113, 114
- Semi-cooperative theory of starch gelatinization, 234–238
- Sequential phase transitions theory (starch gelatinization), 244–249
- Sfbl, 116
- Shearzyme 500L treatment of psyllium, 208, 209–210, 210–211, 211
- Sialic acid-binding adhesin, 121
- Sialylated oligosaccharides, anti-adhesive, 134, 135
 egg yolk-derived, 134, 136–137
- SiiE adhesin, 119
- SLPs (surface-layer proteins) of *Lactobacillus*, 132
- Spirometry, 165–168
 in occupational lung disease, 171
 popcorn workers, 183–184
- Squalene, biosynthesis, 38, 39
- Squalene oxide, 38–45
 cyclization, 41–45
- Starch, 221–267
 functional properties, 223
 gelatinization, 221–222, 223, 230–260
 annealing and its relationship to, 244, 245, 246, 253–255

Starch (*cont.*)

- glass transition and, 255–258
- theories and models, 230–253
- importance, 222
- sources and isolation, 222–223, 223
- structure, 224–230
- Stems, ginsenosides, 24–29
- Stomach acids and ginsenosides, 33, 34, 35, 36
- Streptococcus*
 - S. mutans*
 - adhesin analog activity against, 132–133
 - passive immunization, 130
 - S. pyogenes*/group A adhesins, 116
 - analogs, 133
- Stress, ginsenoside effects, 72–73
- Surface-layer proteins of *Lactobacillus*, 132
- Sympathetic nerve activity and ginsenosides, 72

T

- Tafi* operon, 119
- 2-*Tert*-butylanthraquinone, 57
- TFP (type IV pilus), enterohemorrhagic *E. coli*, 126
- Thiazolidinediones, 78
- Thin-layer chromatography of ginsenosides, 46–48
- Three-stage phase transition theory (starch gelatinization), 250, 258
- Time-of-flight (TOF) MS of ginsenosides
 - quadrupole, 60
 - ultra-performance LC and, 61
- ToxB, 122, 124, 125
- Transition metal cations and ginsenosides, 58
- Triterpenes, biosynthesis, 38
- Triterpinoid saponins, 2
 - dammarane-type *see* Dammarane-type triterpene saponins
 - oleanane-type *see* Oleanane-type triterpene saponins
- TTSS (type III secretion system), 118, 122, 123, 124
- Tumors, malignant *see* Cancer
- Type III, 122, 123

U

- Ultra-performance liquid chromatography of ginsenosides, 61
- Ultraviolet detection, ginsenosides on HPLC, 49–55
- Uropathogenic *E. coli* (UPEC), 102, 114, 126–128
- US Occupational Safety and Health Administration (OSHA) and flavoring-related bronchiolitis obliterans, 179, 185
- UV detection, ginsenosides on HPLC, 49–55

V

- Vaccines, anti-adhesin, 117, 130
- Van der Waals' forces and pathogen adherence, 105, 106
- Vascular effects, ginsenosides, 72–73
- Vina-ginsenoside, 7, 8, 11, 13, 16, 18, 19, 20, 22
- Viscozyme L treatment of psyllium, 208–209, 209–210, 210–211

W

- Water (in starch gelatinization), 230–253
 - sequential phase transitions theory, 244–249
 - two phases, 242
 - water availability theory, 238–241, 243
- Western blots, ginsenosides, 63
- Wheat starch gelatinization, birefringence loss, 235
- Work-related respiratory disease *see* Occupational respiratory disease

X

- X-ray diffraction of starch granules, 228, 231–233
- gelatinization studies, 244

Y

- Yesanichinoside, 5, 7, 22, 23

Z

- Zingibroside, 20